Pfizer Gains FDA Approval for Talazoparib Plus Enzalutamide in HRR-Mutated mAPMN/S Prostate Cancer

SILVER SPRING, MD — The U.S. Food and Drug Administration (FDA) on 26 October 2026 approved talazoparib (Talzenna, Pfizer) in combination with enzalutamide (Xtandi) for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test.

The decision moves the combination into an earlier line of therapy. Talazoparib plus enzalutamide has been approved in the US since June 2023 for HRR-mutated metastatic castration-resistant prostate cancer (mCRPC), based on the TALAPRO-2 trial.

“mAPMN/S” is FDA’s term for disease that has not been treated with androgen pathway drugs or still responds to them. The same population is more widely known as metastatic castration-sensitive or hormone-sensitive prostate cancer (mCSPC or mHSPC).

Approval tied to a companion diagnostic

Patients must have HRR mutations detected by an FDA-authorized test. FDA said it had previously approved FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostic devices to identify eligible patients for this combination.

In the pivotal trial, HRR status was determined prospectively by next-generation sequencing of tumor tissue or circulating tumor DNA (ctDNA). Twelve genes were tested: ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, and RAD51C. The indication covers both BRCA and non-BRCA mutations.

For regulatory and labeling teams, the diagnostic requirement adds a standing control. The drug’s prescribing information, the device labeling, and promotional materials must describe the same patient population in consistent terms.

TALAPRO-3 results

The approval is based on TALAPRO-3 (NCT04821622), a randomized, double-blind, placebo-controlled trial that enrolled 599 patients. All patients received enzalutamide and continuous androgen deprivation therapy, and were randomized 1:1 to add talazoparib or placebo.

Median radiographic progression-free survival (rPFS) was not reached in the talazoparib arm, compared with 45.8 months in the placebo arm. The hazard ratio was 0.48 (95% CI 0.36–0.65; p<0.0001). Investigators assessed rPFS using RECIST version 1.1 and Prostate Cancer Working Group 3 (PCWG3) criteria for bone.

Overall survival data were immature at the time of the rPFS analysis.

The prescribing information includes warnings and precautions for myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), myelosuppression, and embryo-fetal toxicity.

Review pathway

FDA granted the application priority review. The applicant used the Assessment Aid, a voluntary template that organizes the sponsor’s analysis to support FDA’s review.

FDA conducted the review under Project Orbis, the Oncology Center of Excellence framework for concurrent review of oncology products with international partners. Australia’s Therapeutic Goods Administration (TGA) and Health Canada participated, and FDA said their reviews are ongoing.

Pfizer said additional global regulatory filings are planned or underway.

Until other regulators decide, the combination will carry different indications in different markets. Labeling teams typically manage that through version-controlled, market-specific labeling.

What to watch

• Decisions from TGA and Health Canada

• Mature overall survival data from TALAPRO-3

• Whether non-US regulators accept the full 12-gene HRR panel, as FDA did

Source: U.S. Food and Drug Administration, “FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations,” 26 October 2026. Pfizer press release, 26 October 2026. Approval status current as of 27 October 2026.